Abstract The endocannabinoid (eCB) system, consisting of eCB ligands and the type 1 cannabinoid receptor (CB1R), subserves retrograde, activity-dependent synaptic plasticity in the brain. eCB signaling occurs "on-demand," thus the processes regulating synthesis, mobilization and degradation of eCBs are also primary mechanisms for the regulation of CB1R activity. The eCBs, N-arachidonylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), are poorly soluble in water. We hypothesize that their aqueous solubility, and, therefore, their intracellular and transcellular distribution, are facilitated by protein binding. Using in silico docking studies, we have identified the nonspecific lipid binding protein, sterol carrier protein 2 (SCP-2), as a potential AEA binding protein.
Introduction
The endocannabinoid signaling (ECS) system, consisting of the types 1 and 2 cannabinoid receptors (CB1R and CB2R, respectively) and endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and N-arachidonylethanolamine (AEA), modulates cellular responses during a variety of physiological and pathological conditions [1] . Alterations in brain ECS, resulting from changes in either CB1R/CB2R signaling or availability of the eCBs, have been seen in a variety of pathological states including obesity, neurodegeneration, pain, inflammation, and psychiatric disorders.
The eCBs are highly lipophilic and poorly water soluble. Their high lipophilicity allows the eCBs to be released in a non-vesicular manner since they can freely cross the plasma membrane. However, their low aqueous solubility poses a problem for intracellular trafficking and leads to the hypothesis that there are eCB binding proteins that enhance aqueous solubility and movement across aqueous barriers [2, 3] . Indeed, other lipid signaling molecules, such as steroids, bind to intracellular proteins that facilitate their sequestration and trafficking within cells [4] . Findings that the enzymes and substrate for AEA synthesis [5] and degradation [6] are found in intracellular membranes suggest that AEA is trafficked intracellularly between organelles and the plasma membrane. Furthermore, AEA is accumulated within cells far beyond equilibrium, a finding that is consistent with an intracellular binding protein that serves a sequestration role [3] . The enzymes involved in 2-AG synthesis [7] and degradation [8] are present at the plasma membrane, suggesting that 2-AG signaling does not require intracellular trafficking and, thus, not involve an intracellular binding protein.
A number of proteins have been suggested to function as AEA binding proteins, including fatty acid binding proteins (FABP) 5 and 7 [9] , albumin and heat shock protein 70 [10] . However, the primary FABP present in adult brain (HFABP, also called FABP3) [11] does not contribute to AEA uptake [9] while neither FABP5 nor FABP7 are expressed in significant amounts in adult neurons [11, 12] . FABP7 (also called BFABP) is highly expressed in radial glial cells and is hypothesized to play an important role in myelination [13] . Albumin and heat shock protein 70 have very limited expression in normal brain, only appearing during stroke or with a compromised blood brain barrier [14] . FLAT, a truncated version of fatty acid amide hydrolase (FAAH), has been recently reported to bind AEA in a saturable manner that also exhibits competition by AEA analogs [15] . However, neurons from FAAH null mice accumulate AEA at wild type amounts [16] , suggesting that additional proteins are involved in intracellular sequestration of AEA. Thus, it is likely that additional proteins can serve as AEA carriers.
In this study, we identify sterol carrier protein 2 (SCP-2) as an additional intracellular protein that could contribute to AEA cellular uptake and/or accumulation. SCP-2 is a multisubstrate, lipid binding protein that shuttles cholesterol and other lipids from the endoplasmic reticulum, where they are synthesized, to the cell surface [17] . SCP-2 can bind a variety of structurally diverse lipids, including fatty acids, fatty acyl CoA derivatives, sterols and phospholipids [18] . SCP-2 binds fatty acids and their CoA derivatives with K d values in the 10 −9 -10 −7 M range [18] . Importantly, SCP-2 is expressed in the brain and is enriched in synaptosomal preparations [19, 20] . The purpose of these studies is to test the hypothesis that SCP-2 binds AEA and contributes to its cellular uptake and/or sequestration.
In support of this hypothesis, we report molecular docking studies which demonstrate a moderate but favorable free energy of binding (ΔG) of AEA to SCP-2. We report further that AEA is predicted to bind within the hydrophobic cavity proposed as the SCP-2 substrate binding site [21] . In addition, AEA inhibits SCP-2-dependent trafficking of cholesterol in vitro and heterologous SCP-2 expression increases the accumulation of AEA in HEK 293 cells at early time points after its addition. However, SCP-2 expression does not affect intracellular AEA concentrations at steady state. Together, these data support the hypothesis that SCP-2 binds AEA with moderate affinity and can increase the amount of AEA taken up by cells but does not affect the extent of accumulation with long incubation times. Thus SCP-2 has the characteristics of an AEA uptake facilitator but not an intracellular sequestration site for AEA.
Materials and Methods

Materials
Human SCP-2 protein expression vectors were purchased from GeneCopoeia (Rockville, MD) and were based upon previous reports [22] . L1210 cells were the kind gift of Dr. Albert Girotti (Medical College of Wisconsin). Human embryonic kidney (HEK 293) cells were obtained from American Type Culture Collection (Manassas, VA, USA). Polyclonal antibodies against SCP-2 were obtained from Santa Cruz Biochemicals; and ß-actin from Sigma; secondary antibodies used were goat-anti-rabbit IgG HRP (GE Bio-Sciences, Pittsburg, PA, USA) and goat-anti-mouse IgG HRP (Sigma). Computational Docking AutoDock 4.2 [23] was used to dock cholesterol, AEA, 2-AG, AM-404 and arachidonic acid into the NMR structure of SCP-2 (1qnd, www.pdb.org) [21] in silico, as generally described elsewhere [24] . Briefly, co-crystallized waters and bound ligand (16-doxylstearic acid) were removed and a grid of dimensions 22.5×15×18.75 Å surrounding the hydrophobic binding site was created using GRID. The substrate binding site was compared to a crystal structure of a homologous protein, human peroxisomal multifunctional enzyme type 2 (MFE-2), bound by a lipid substrate, Triton-X (Fig. S1 ). Molecular structures of cholesterol, AEA, 2-AG, and AM-404 were downloaded from PubChem (pubchem.ncbi.nlm.nih.gov) and converted to mol2 files using Open Babel ( [25] ; The Open Babel Package, V. 2.0. 2., http://openbabel.org). Arachidonic acid was generated and energy-minimized using Chem3D Pro 12.0 (CambridgeSoft, Inc.). Rigid amino acid side chains were maintained in SCP-2. AutoDock Tools was used to prepare both protein and ligands for docking, including addition of Gasteiger charges. All ligands were docked in their physiologically relevant ionization state (at pH 7.4). Each compound was docked into the hydrophobic binding site using 100 genetic algorithm optimization runs. Results were clustered according to lowest binding energy (ΔG). The lowest mean free energy of binding was then selected as the putative average binding mode.
Preparation of Recombinant SCP-2 SCP-2 was expressed in E. coli and purified according to previously reported protocols [26] . The protein was stored at −20°C in 50 % glycerol (1-6 mg/ml protein) to retain activity over time. Confirmation of purity was determined through Coomassie staining of SDS-PAGE gels.
Assay of SCP-2-Dependent Cholesterol Transfer
Small unilamellar vesicles (SUVs) were created and the cholesterol transfer assay was designed based on previous methods [27] . Briefly, the SUVs were formed from 0.5 mM POPC, 0.4 mM cholesterol and 0.01 mM dicetyl phosphate (DCP) and [ 14 C]cholesterol (1 μCi/1 ml of SUVs) in phosphate-buffered saline (PBS) using an extrusion method. ] contents of both were determined using liquid scintillation counting. Percent uptake was calculated as dpm cells/(dpm cells + dpm buffer). Nonspecific uptake was measured in the presence of 100 μM AEA.
Statistics
One-or two-way analyses of variance (ANOVAs) were carried out using GraphPad Prism. Significant effects in the ANOVA were followed by Bonferroni's t-tests. For the AEA uptake studies, comparisons planned prior to the study were analyzed in the absence of a significant ANOVA. A p value of less than 0.05 was considered as the threshold for a significant difference.
Results
Arachidonate Analogues Bind Within the Proposed Sterol Binding Pocket of SCP-2
Automated docking of cholesterol, arachidonic acid, AEA, 2-AG, and AM404 to SCP-2 was accomplished using the SCP-2 NMR structure determined by Garcia et al. [21] , focusing on the hydrophobic cavity containing Thr85 and Gly86. Of the compounds examined, cholesterol (ΔG=−6.62 kcal/mol) docked with the lowest free energy of binding in this site (Table 1) . AEA (ΔG=−3.60 kcal/mol) and 2-AG (ΔG=−2.80 kcal/mol) bound SCP-2 with higher free energy than cholesterol. Arachidonic acid bound with lower energy (ΔG=−4.60 kcal/mol) than AEA. N-Arachidonylaminophenol (AM404), an inhibitor of AEA accumulation by neurons [28] , showed the lowest mean free energy of binding (ΔG=−4.80 kcal/mol) of the fatty acid analogues studied. Figure 1 shows orientations of cholesterol, AEA, arachidonic acid, and AM404 within the active site. Cholesterol was found to engage in hydrogen bond-donating interactions with Met84 and Gln115. The lipophilic tail recognizes the In order to determine whether AEA can bind SCP-2, we performed in vitro experiments using purified SCP-2 protein.
In accord with earlier studies, we found that the presence of recombinant SCP-2 enhances the transfer of cholesterol from SUVs to acceptor L1210 cells in a dose and time dependent fashion (Fig. 2a) . Following a 1-h incubation, nearly three times more [ (Fig. 2b) . Post-hoc tests reveal that both 50 and 250 μM AEA produce significant reductions in the amount of [ 
Initial AEA Uptake into HEK 293 Cells is Increased by SCP-2 Expression
To determine whether SCP-2 facilitates cellular uptake of AEA, SCP-2 was transiently expressed in HEK 293 cells. Untransfected HEK 293 cells do not exhibit detectable amounts of SCP-2 and expression of the SCP-2 plasmid led to a measureable amount of SCP-2 protein (Fig. 3) . Untransfected HEK 293 cells rapidly accumulate [ (Fig. 4) . However, the plateau values determined by fitting the uptake data to the single order association equation are the same regardless of the incubation temperature of the cells (Fig. 5a ). The expression of SCP-2 exerts a temperaturesensitive increase in the uptake of AEA in the first 5 min after addition (Fig. 4) . Two-way analysis of the plateau values reveals significant main effects of both SCP-2 (F 1,27 =17.2; p<0.0005) and temperature (F 2,27 =4.4; p<0.05) without a significant interaction. Planned post hoc comparisons reveal that AEA uptake in SCP-2 expressing cells reaches a significantly higher plateau at incubation temperatures of 22°and 37°, but not at 4°C (Fig. 5a ). Two-way ANOVA was also applied to the rate constant (K) for the uptake process (Fig. 5b) . The presence of SCP-2 exerted a significant main effect on the rate constant (F 1,27 =7.7; p<0.01) but temperature did not (F 2,27 =2.4, n.s.). Planned post hoc comparisons indicate that K is significantly decreased in cells expressing SCP-2 at 22°C incubation.
SCP-2 Does Not Alter [ 3 H]AEA Accumulation at Equilibrium
To test the hypothesis that SCP-2 serves as a sequestration site for AEA, we examined the amount of [ (Fig. 6) , which is consistent with a saturable sequestration of AEA. However, the addition of SCP-2 to the HEK 293 cells did not alter the competition isotherms for any of the competing ligands. The composite IC 50 values and the bottom of the inhibition curves are provided in Table 2 . In all cases, the 95 % confidence intervals are overlapping, which indicates that there are no significant effects of SCP-2 expression on these parameters. 
Discussion
These studies support the hypothesis that SCP-2 can bind to AEA and other arachidonic acid analogs. In silico docking studies indicate that the arachidonates bind to the same site as cholesterol but with higher relative free energy, which suggests they have lower affinity for the binding site than cholesterol. In support of the predictions from the docking studies, we found that AEA competes with cholesterol for SCP-2 binding using an in vitro cholesterol transfer assay; however, the concentration of AEA required is high. Although heterologous expression of SCP-2 in HEK 293 cells enhances the initial uptake of AEA at 22°and 37°C, the presence of SCP-2 does not increase the amount of AEA associated with cells at equilibrium. SCP-2 does not alter the IC50 values for competitors to reduce AEA sequestration at equilibrium. We conclude that SCP-2 reduces a barrier to the entry of AEA into cells, but is not functioning as a sequestration or long term binding site for the lipid. It is possible that SCP-2 serves as a transport protein for AEA, moving it to an ultimate sequestration site that has higher affinity for AEA than SCP-2.
SCP-2 is a multi-purpose lipid binding protein that shuttles cholesterol and other lipids from the endoplasmic reticulum, where they are synthesized, to the cell surface [18] . SCP-2 can bind many types of lipid, including fatty acids, fatty acyl CoA derivatives and phospholipids [18] . SCP-2 is expressed in the brain and is enriched in synaptosomal preparations [19, 29] , suggesting that it plays a role in synaptic transmission. Schroeder and colleagues have described a mechanism by which SCP-2 shuttles its lipophilic cargo to a desired area in the cell [18] . According to their model, the N terminus of SCP-2 contains an amphipathic alpha helix that allows for association with acidic-phospholipid-rich membranes. This results in the association of SCP-2 with the internal leaflet of the plasma membrane. SCP-2 preferentially associates with negatively charged lipids and the radius of lipid curvature is an important determinant of SCP-2 interactions [30, 31] .
Our automated docking studies provide the first detailed (atomic-level) evaluation of a molecular mechanism of action governing SCP-2 recognition and trafficking of endogenous lipids. Previous structural studies of SCP-2 [21] point to a singular lipophilic cavity that binds and transports hydrophobic substrates. Docking and comparison with homologous human proteins have allowed us to identify the likely pocket in SCP-2 that is responsible for lipid/eicosanoid and steroid transport. Focusing our efforts on this cavity gave us detailed information regarding putative binding modes for various proposed ligands and the relative free energies (ΔG) of binding for sterol and eicosanoid structural motifs. It is interesting to note that arachidonate analogues did not adopt consensus orientations within the binding site. Anionic arachidonates (arachidonic acid, 16-doxyl-stearic acid) maximized ionic interactions with Lys122; however, N-arachidonoyl carboxamides (AEA, AM404) differed in the orientations of their respective head groups. The ethanolamide of AEA maximizes hydrogen bonding interactions with Lys122 and Asn89, though the hydrophobic tails of arachidonic acid and AEA orient in opposite directions toward the lipophilic cleft (Fig. 1b, c) . AM404 is not predicted to engage with Lys122, instead maximizing hydrogen bond-donating character with Met84, similar to cholesterol (Fig. 1a) . Unique to AM404, the 4-phenol functionality simultaneously engages in hydrogen bond-donating and -accepting interactions with Gly119 (Fig. 1d) . Relative calculated ΔG values indicate favorable energetics of binding of rank order of: cholesterol > AM404=arachidonic acid > AEA > 2-AG. Thus, the docking studies predict that arachidonates, including those with a modified head group, bind to the putative lipid cargo binding site of SCP-2.
A prediction of the docking studies is that the arachidonates should compete for and, thus, inhibit, the binding and transport of cholesterol by SCP-2. To test this prediction, we used an in vitro assay of SCP-2 enhancement of cholesterol transport. In agreement with the prediction of the docking studies, we found that AEA inhibited the transfer of cholesterol between SUVs and cells at micromolar concentrations. We attempted to establish an AEA transport assay, using radiolabelled AEA in place of cholesterol, but could not measure a reliable signal. We assume this is because the binding of AEA is too low to be detected.
Previous studies have shown that extracellularly administered AEA rapidly enters cells in a manner that is consistent with facilitated diffusion [32] . Since SCP-2 has been shown to traffic lipids, such as cholesterol, across aqueous barriers, we tested the hypothesis that the addition of SCP-2 would enhance cellular uptake of AEA. A second hypothesis that we considered is that SCP-2 serves as an intracellular sequestration site for AEA. To test the first hypothesis, HEK 293 cells were transiently transfected with SCP-2 for 24 h then the accumulation of labeled AEA was determined for 5 min after its addition to the extracellular media. Untransfected HEK 293 cells take up AEA and the plateau reached is the same whether the cells are incubated at 4°C or 37°C. These data are consistent with cell entry via passive diffusion. When SCP-2 is expressed, a clear increase in accumulation is seen throughout the time course in cells incubated at 37°C. Comparison of the plateau and rate constant values predicted by the fit of these data to a single site association equation demonstrate that the SCP-2 expressing cells accumulate AEA to a greater plateau value than control without a significant change in the rate constant. Interestingly, the cells incubated at 22°C, but not those incubated at 4°C, also have a significant increase in plateau value. These data are consistent with the hypothesis that the presence of SCP-2 decreases a barrier that retards the initial accumulation of AEA by HEK 293 cells. It is our hypothesis that SCP-2 functions to desorb AEA from the plasma membrane and traffic it to other intracellular organelles, a mechanism that is consistent with the known effect of SCP-2 to traffic lipids, such as cholesterol, between intracellular compartments [33] .
Our second hypothesis was that SCP-2 also functions as an intracellular sequestration site for AEA. A prediction of this hypothesis is that the addition of SCP-2 to a cell should increase its intracellular concentration at equilibrium. Our results with competing arachidonates (unlabeled AEA; AM404 and 2-AG) demonstrate that all three compete with the accumulation of [ [34] . These data indicate that the steady state accumulation of [ 3 H]AEA is saturable, which is consistent with a protein binding site serving as a sequestration mechanism [3] . Surprisingly, the expression of SCP-2 affected neither the total [ Vertical lines represent SEM. Data were analyzed using two-way ANOVA, with SCP-2 transfection status and incubation temperature as main effects. *p<0.05 and **p<0.01 compared to the control transfected data at the same temperature using Bonferroni's t-tests These findings suggest that there is another protein or process in HEK 293 cells that serves as an AEA sequestration site. A series of studies by Kaczocha and Deutsch demonstrate that two FABPs, 5 (also called EFABP and KFABP) and 7 ( a l s o c a l l e d B FA B P ) b i n d A E A a n d o t h e r Nacylethanolamines at micromolar concentrations and function as intracellular transporters in several cell types [9, 36] .
HEK293 cells have been shown to express FABP7 [37] , so it is possible that this protein is responsible for the accumulation of AEA. Recent data in sensory neurons support the importance of FABP's in the cellular uptake of AEA, particularly under pathological conditions [38] .
Through multiple approaches, these data support the hypothesis that SCP-2 can bind to the AEA in the micromolar range. Given that the concentrations of AEA in brain tissue are measured in the nanomolar range, it is likely that a small fraction of the available AEA would be bound to SCP-2. However, our data also indicate that the presence of SCP-2 in a model cell increases the initial uptake of AEA. Furthermore, the hypothesis that brain AEA is inactivated through a reuptake process has been proposed and is supported by data from isolated neurons and pharmacological inhibitors [3] . SCP-2 is present in brain, specifically in synaptosomes, which are preparations from brain that are enriched in presynaptic nerve terminals [20] . Interestingly, ethanol also competes with cholesterol for binding to SCP-2 at pharmacologically relevant concentrations [19] and acute exposure of rats to ethanol decreases total [39] and extracellular [40] AEA concentrations in the nucleus accumbens. As the effects of ethanol on tissue AEA concentrations are not due to changes in synthesis or FAAH-mediated hydrolysis of AEA [39] , the present study suggests the hypothesis that ethanol and AEA share binding to SCP-2 and could influence each other through that mechanism. Genetic screens have found that SCP-2 gene (scp2) expression is reduced in several important neuropsychiatric disorders. For example, scp2 expression is reduced significantly in the frontal cortex, striatum and midbrain in the wiggle rat, a congenic rat with behavioral characteristics that are similar to attention deficit, hyperactivity disorder in humans [41] . A genome wide association study recently identified scp2 as a candidate gene for narcolepsy [42] . Thus, regardless of the interactions with the ECS, SCP-2 likely has important roles in brain function that deserve more attention. 
